Amundi Pioneer Asset Management Inc. Raises Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Amundi Pioneer Asset Management Inc. increased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 44.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,799,877 shares of the company’s stock after acquiring an additional 3,653,654 shares during the quarter. Amundi Pioneer Asset Management Inc.’s holdings in Elanco Animal Health were worth $361,902,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in shares of Elanco Animal Health during the 3rd quarter worth approximately $41,000. Graves Light Private Wealth Management Inc. acquired a new position in Elanco Animal Health during the 4th quarter valued at approximately $68,000. Winslow Evans & Crocker Inc. acquired a new position in Elanco Animal Health during the 4th quarter valued at approximately $73,000. NuWave Investment Management LLC increased its position in shares of Elanco Animal Health by 2,645.2% in the 4th quarter. NuWave Investment Management LLC now owns 4,255 shares of the company’s stock valued at $131,000 after acquiring an additional 4,100 shares during the period. Finally, Veriti Management LLC acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at $133,000. Hedge funds and other institutional investors own 86.83% of the company’s stock.

ELAN stock opened at $29.81 on Thursday. The company’s 50-day simple moving average is $30.95 and its 200-day simple moving average is $30.34. The company has a quick ratio of 0.90, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Elanco Animal Health Incorporated has a 52-week low of $18.37 and a 52-week high of $34.81. The firm has a market cap of $14.09 billion, a P/E ratio of -52.30, a PEG ratio of 4.13 and a beta of 0.86.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, February 23rd. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.03. Elanco Animal Health had a negative net margin of 8.45% and a positive return on equity of 3.43%. On average, analysts anticipate that Elanco Animal Health Incorporated will post 0.44 earnings per share for the current fiscal year.

Several equities analysts recently issued reports on ELAN shares. Zacks Investment Research raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Thursday, February 25th. Raymond James reissued a “hold” rating on shares of Elanco Animal Health in a research report on Monday, March 22nd. Argus downgraded Elanco Animal Health from a “buy” rating to a “hold” rating in a research report on Wednesday, December 9th. Gabelli reissued a “hold” rating and issued a $32.00 target price on shares of Elanco Animal Health in a research report on Monday, March 29th. Finally, Credit Suisse Group raised shares of Elanco Animal Health from a “neutral” rating to an “outperform” rating and upped their price target for the company from $33.00 to $38.00 in a report on Thursday, March 4th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. Elanco Animal Health presently has a consensus rating of “Hold” and a consensus price target of $31.68.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Further Reading: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.